Michael Flynn departs the E. Barrett Prettyman Courthouse. Photo: Aaron P. Bernstein/Getty Images

President Trump's former national security adviser Michael Flynn, who awaits sentencing for lying to federal investigators, will serve as the director of global strategy for a new lobbying and consulting firm called Stonington Global, reports the Wall Street Journal.

The details: The firm was founded by Washington lobbyist Nick Muzin, a registered foreign agent who most recently worked on an influence campaign for the government of Qatar. Muzin was named in a lawsuit against the Qatari government filed by Republican fundraiser Elliot Broidy, which alleged that the Gulf state had conspired with Muzin to hack Broidy's emails and smear his reputation.

Go deeper

Updated 49 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Chris Christie: Wear a mask "or you may regret it — as I did" — Senate Democrats block vote on McConnell's targeted relief bill.
  2. Business: New state unemployment filings fall.
  3. Economy: Why the stimulus delay isn't a crisis (yet).
  4. Health: FDA approves Gilead's remdesivir as a coronavirus treatment How the pandemic might endMany U.S. deaths were avoidable.
  5. Education: Boston and Chicago send students back home for online learning.
  6. World: Spain and France exceed 1 million cases.

FBI: Russian hacking group stole data after targeting local governments

FBI Headquarters. Photo: Mark Wilson/Getty Images

Energetic Bear, a Russian state-sponsored hacking group, has stolen data from two servers after targeting state and federal government networks in the U.S. since at least September, the FBI and Cybersecurity and Infrastructure Security Agency said on Thursday.

Driving the news: Director of National Intelligence John Ratcliffe announced Wednesday that Iran and Russia had obtained voter registration information that could be used to undermine confidence in the U.S. election system.

FDA approves Gilead's remdesivir as a coronavirus treatment

A production line of Remdesivir. Photo: Fadel Dawood/picture alliance via Getty Images

Gilead Sciences on Thursday received approval from the Food and Drug Administration for remdesivir, an antiviral treatment that has shown modest results against treating COVID-19.

Why it matters: It's the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.